Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1PFE trade ideas

Pfizer in a bull flag.Pfizer - 30d expiry - We look to Buy a break of 48.31 (stop at 46.56) Short term bias has turned positive. Posted a bullish Flag formation. A break of 48.26 is needed to confirm the outlook. A break of the recent high at 48.26 should result in a further move higher. Short term momentum is bullish. This stock has seen good sales growth. The bias is to break to the upside. Our profit targets will be 52.69 and 53.69 Resistance: 48.00 / 49.70 / 52.00 Support: 46.70 / 46.00 / 44.70 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFELong
by Saxo
1
PFE longWednesday morning, Pfizer unveiled its Q2 figures. They revealed that the pharmaceutical sector giant earned revenue of $19 billion, a robust 86% higher than in the same quarter of 2020. Much of this was, of course, due to the BNT162b2 coronavirus vaccine it's developed with Germany-based BioNTech. But even stripping out the vaccine's sales from the top line, the company still managed to grow revenue by 10% to $11.1 billion. On average, analysts tracking Pfizer stock were modeling $18.45 billion. Quoted by the company as saying the quarter was "remarkable," CEO Albert Bourla signaled optimism for the coming years. He and his troops believe Pfizer will be able to hit a 6% compound annual revenue growth rate through 2025. With that powerful quarter behind it, the confident Pfizer has upped its full-year guidance. It now expects $78 billion to $80 billion in revenue (previous estimate: $70.5 billion to $72.5 billion), and adjusted diluted per-share earnings of $3.95 to $4.05 (up from $3.55 to $3.65).
NYSE:PFELong
by MaDasurfer
6
PFE (Range Trade)Since the recent news relative to the authorization this past week, price has been making higher highs and lower lows. Only 6 times this year price played around in the $54 -$56 area. I'm banking on price exhaustion from the recent "good" news this past week. Daily is overbought as well. Maybe we can get a bar close or two this week lower than previous to give us some time. If price reaches this resistance area, we will reassess Might wait til the fed decision and cpi reports pass next week to get a second look.
NYSE:PFEShort
by Redimere_91
PFIZER Broke above its 2022 Bear Channel!Pfizer (PFE) broke and closed today above the Channel Down that has been dominating the 2022 Bear Market since the January 11 High. At the same time the 1D RSI has been ranging and while the 1D MA200 (orange trend-line) held successfully last time, we do expect one last test or for an even more comfortable long-term buy, the 1D MA50 (blue trend-line). As you may notice, the Fibonacci retracement levels since the All Time High, formed solid Resistance and Support levels during the downtrend, so after the next pull-back our target will by the 0.786 Fib at 57.35. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFE
by TradingShot
2
PFE, 10d+/13.88%rsing cycle 13.88% more than 10 days. ================================================================================================================================================================== This data is analyzed by robots. Analyze historical trends based on The Adam Theory of Markets (20 moving averages/60 moving averages/120 moving averages/240 moving averages) and estimate the trend in the next 10 days. The white line is the robot's expected price, and the upper and lower horizontal line stop loss and stop profit prices have no financial basis. The results are for reference only.
NYSE:PFELong
by Tonyder
PfizerLiedPeopleDiedPfizer (NYSE:PFE) said its bivalent RSV vaccine candidate met a main goal of showing efficacy against severe disease but did not reach statistical success in the second main objective in a phase 3 trial in pregnant women who given the vaccine to help protect their infants from RSV disease after birth. The phase 3 study, dubbed MATISSE, evaluated the bivalent RSV prefusion vaccine RSVpreF (PF-06928316) against placebo to test efficacy against medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI in infants born to healthy women vaccinated during pregnancy. The study enrolled ~7.4K pregnant individuals who received RSVpreF or placebo during the late second to third trimester of their pregnancy.Pfizer said that an interim efficacy analysis met the success criterion for one main goal. The observed efficacy for severe MA-LRTI was 81.8% through the first 90 days of life, and efficacy of 69.4% was seen for infants over the six-month follow-up period. The company noted that although the statistical success criterion was not met for the second primary goal, clinically meaningful efficacy was seen for MA-LRTI of 57.1% in infants from birth through the first 90 days of life. Meanwhile, efficacy for MA-LRTI of 51.3% was observed over the six-month follow up period.The vaccine was well-tolerated with no safety concerns for the individuals and their newborns, the company noted. Pfizer said that at the recommendation of a Data Monitoring Committee (DMC), and in consultation with the U.S. Food and Drug Administration (FDA), the company has stopped enrollment in the study. Based on these results Pfizer plans to submit an application to the FDA by the end of 2022 seeking approval of the vaccine. IF #PfizerLiedPeopleDied is trending, possibly it is time for Short, just thoughts. The investments and idea published may not be suitable for all investors. If you have any doubts as to the merits of an investment, you should seek advice from independent financial advisor or other professionals to determine what may be best for your individual needs. We do not and cannot guarantee that your use of our APP and/or any of its features will generate profits. All opinions, news, reviews, research, analysis, prices, or other information contained on or provided via this site are provided on an “as is” basis as general market commentary and/or expressions of opinion only. Information may not be complete, accurate or up to date and may not be suitable for every individual, nor be a suitable basis for an investment decision. No representation, warranty, undertaking, assurance or guarantee (express or implied) is made or given as to the availability, adequacy, accuracy, completeness, reasonableness or appropriateness of any of the information or opinions provided or expressed on or through this site. There is no obligation to notify you of any corrections or modifications.
NYSE:PFEShort
by SoundsgoodTFtalks